Literature DB >> 15833506

Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.

Hann-Chorng Kuo1.   

Abstract

OBJECTIVES: To evaluate, in a prospective study, the effectiveness of prostate injection of botulinum A toxin in patients who were poor surgical candidates. Patients with benign prostatic hyperplasia (BPH) are usually successfully treated with medical treatment or transurethral resection. However, some patients with chronic urinary retention or a large postvoid residual urine volume due to BPH are poor surgical candidates or are patients in whom medical treatment has failed.
METHODS: Ten patients with BPH and urinary retention or a large postvoid residual urine volume received 200 U botulinum A toxin injection into the transition zone of the prostate. The clinical results and urodynamic parameters at baseline and after treatment were compared.
RESULTS: All patients had an improvement in spontaneous voiding after treatment. Of them, 8 had an excellent result (80%) and 2 had an improved result. Both voiding pressure and postvoid residual volume were significantly decreased after treatment. The total prostate volume was significantly reduced, and the maximal flow rate was significantly increased after treatment. The maximal effects of botulinum A toxin appeared at about 1 week and were maintained at 3 and 6 months after treatment. At 6 to 12 months (mean 9) of follow-up, no patient had had recurrence of urinary retention and the voiding condition in all patients remained at the post-treatment status. No adverse effect was noted.
CONCLUSIONS: Prostate injection of botulinum A toxin is an effective alternative treatment with minimal adverse effects for patients with benign prostatic obstruction who are poor surgical candidates or in whom medical treatment has failed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833506     DOI: 10.1016/j.urology.2004.10.077

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  33 in total

1.  [S2e guideline of the German urologists: Instrumental treatment of benign prostatic hyperplasia].

Authors:  T Bschleipfer; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; K Höfner
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

Review 2.  Other therapies for BPH patients: desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin.

Authors:  Abdel-Rahmène Azzouzi; Marc Fourmarier; Francois Desgrandchamps; Charles Ballereau; Christian Saussine; Olivier Haillot; Bertrand Lukacs; Marian Devonec; Alexandre de la Taille
Journal:  World J Urol       Date:  2006-05-18       Impact factor: 4.226

Review 3.  Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.

Authors:  Catherine A Thomas; Yao-Chi Chuang; Antonella Giannantoni; Michael B Chancellor
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

4.  The use of botulinum toxin in men with benign prostatic hyperplasia.

Authors:  Susan R Rusnack; Steven A Kaplan
Journal:  Rev Urol       Date:  2005

5.  [Intraprostatic injection therapy in patients with benign prostatic syndrome].

Authors:  T Bschleipfer; T Bach; C Gratzke; S Madersbacher; M Oelke
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

Review 6.  A review of botulinum toxin use for chronic pelvic pain syndrome.

Authors:  Henry P Gottsch; Claire C Yang; Richard E Berger
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

7.  Intravesical botulinum toxin for lower urinary tract dysfunction.

Authors:  Marcus John Drake
Journal:  F1000 Med Rep       Date:  2010-01-27

Review 8.  [Botulinum toxin in the treatment of benign prostatic hyperplasia : an overview].

Authors:  S Boy; C Seif; P M Braun; K-P Jünemann
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

Review 9.  Hitting below the belt (bladder): botulinum treatment of urethral and prostate disorders.

Authors:  H Henry Lai; Christopher P Smith
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

10.  Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.

Authors:  João Silva; Rui Pinto; Tiago Carvalho; Francisco Botelho; Pedro Silva; Rui Oliveira; Carlos Silva; Francisco Cruz; Paulo Dinis
Journal:  BMC Urol       Date:  2009-08-15       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.